--- title: "High Growth Tech Stocks To Watch In Asia December 2025" description: "Asian tech stocks are gaining attention for high growth potential amid mixed economic indicators. Key companies include Shengyi Technology, Giant Network Group, and CARsgen Therapeutics, showing stron" type: "news" locale: "en" url: "https://longbridge.com/en/news/269366138.md" published_at: "2025-12-11T10:30:42.000Z" --- # High Growth Tech Stocks To Watch In Asia December 2025 > Asian tech stocks are gaining attention for high growth potential amid mixed economic indicators. Key companies include Shengyi Technology, Giant Network Group, and CARsgen Therapeutics, showing strong revenue and earnings growth. Shanghai OPM Biosciences and Kakaku.com are highlighted for their robust performance and strategic R&D investments. CELSYS is noted for its share repurchase program and strong sales. Simply Wall St offers a comprehensive analysis of 187 high growth tech stocks in Asia. As Asian markets navigate a complex landscape marked by mixed economic indicators and evolving investor sentiment, the region's technology sector continues to capture attention with its potential for high growth. In this environment, identifying promising tech stocks involves looking for companies that demonstrate resilience and innovation amidst shifting global trends and local challenges. ### Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Shengyi TechnologyLtd 21.50% 32.87% ★★★★★★ Giant Network Group 34.73% 40.54% ★★★★★★ Fositek 37.83% 51.54% ★★★★★★ Suzhou TFC Optical Communication 35.80% 36.87% ★★★★★★ Gold Circuit Electronics 29.41% 37.22% ★★★★★★ Zhongji Innolight 34.82% 35.50% ★★★★★★ Shengyi Electronics 24.67% 33.32% ★★★★★★ eWeLLLtd 21.55% 22.80% ★★★★★★ Co-Tech Development 35.68% 75.80% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★ Click here to see the full list of 187 stocks from our Asian High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. ## Shanghai OPM Biosciences (SHSE:688293) **Simply Wall St Growth Rating:** ★★★★☆☆ **Overview:** Shanghai OPM Biosciences Co., Ltd. is engaged in providing cell culture media and CDMO services both in China and internationally, with a market cap of CN¥5.90 billion. **Operations:** OPM Biosciences generates revenue primarily through its cell culture media and CDMO services. The company operates both domestically in China and internationally, with a market cap of CN¥5.90 billion. Shanghai OPM Biosciences has demonstrated robust growth in the competitive biotech sector, with a notable 25.8% increase in revenue to CNY 271.53 million and a surge in net income by 81.4% to CNY 49.43 million for the first nine months of 2025. These financial gains reflect a strategic emphasis on R&D, crucial for maintaining technological leadership and innovation within Asia's high-growth markets. Despite facing challenges like a highly volatile share price and low forecasted Return on Equity at just 7%, the company's earnings growth of 46.46% annually outpaces the broader Chinese market's expansion rate significantly, showcasing its potential amidst fierce industry competition and evolving market demands. - Get an in-depth perspective on Shanghai OPM Biosciences' performance by reading our health report here. - Assess Shanghai OPM Biosciences' past performance with our detailed historical performance reports. ## Kakaku.com (TSE:2371) **Simply Wall St Growth Rating:** ★★★★☆☆ **Overview:** Kakaku.com, Inc., along with its subsidiaries, offers purchase support and restaurant review services in Japan and has a market capitalization of ¥454.33 billion. **Operations:** The company generates revenue primarily through its Kakaku.Com segment, contributing ¥24.04 billion, and Tabelog segment with ¥36.75 billion, focusing on purchase support and restaurant reviews in Japan. The Kyujin Box and Incubation segments add additional income streams of ¥17.31 billion and ¥8.91 billion respectively, highlighting a diversified business model within the digital services sector. Kakaku.com, renowned for its robust platform in price comparison and consumer services, is navigating through an evolving market landscape with a steady commitment to innovation. With an 11.7% annual revenue growth and a 12.5% increase in earnings per year, the company outstrips Japan's average market expansion of 4.6%. Despite not leading the pack in high-growth sectors, Kakaku.com maintains a competitive edge through strategic R&D investments and high-quality earnings that solidify its market position. Recent affirmations of consistent dividends underscore financial stability, appealing to stakeholders looking for reliable returns amidst dynamic market conditions. - Navigate through the intricacies of Kakaku.com with our comprehensive health report here. - Evaluate Kakaku.com's historical performance by accessing our past performance report. ## CELSYS (TSE:3663) **Simply Wall St Growth Rating:** ★★★★☆☆ **Overview:** CELSYS, Inc. operates in the content creation solutions sector in Japan and has a market capitalization of ¥49.61 billion. **Operations:** CELSYS, Inc. specializes in providing content creation solutions within Japan. The company generates revenue primarily through software sales and related services, focusing on digital illustration, manga, and animation tools. CELSYS is capturing attention with its strategic share repurchase program, signaling confidence in its financial health and commitment to shareholder value. This initiative complements the company's robust performance, highlighted by a revised earnings forecast that surpasses previous expectations due to strong sales from both one-time purchases and subscription models of its flagship software, CLIP STUDIO PAINT. With an impressive 27.2% expected annual earnings growth and a revenue increase of 9% per year—outpacing the Japanese market average—CELSYS is poised for continued success in the competitive tech landscape. - Click here and access our complete health analysis report to understand the dynamics of CELSYS. - Gain insights into CELSYS' past trends and performance with our Past report. ## Taking Advantage - Discover the full array of 187 Asian High Growth Tech and AI Stocks right here. - Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. - Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. ## Curious About Other Options? - Explore high-performing small cap companies that haven't yet garnered significant analyst attention. - Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. - Find companies with promising cash flow potential yet trading below their fair value. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Related Stocks - [002558.CN - Giant Network](https://longbridge.com/en/quote/002558.CN.md) - [02171.HK - CARSGEN-B](https://longbridge.com/en/quote/02171.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 科济药业-B 向港交所提交披露文件，计划以每股 16.52 港元的价格回购 245,000 股 | CARsgen Therapeutics Holdings Ltd. 在香港证券交易所的备案中披露回购了 245,000 股普通股，每股价格为 16.52 港元，总计 4,047,240.00 港元。该信息于 2026 年 1 月 23 日 | [Link](https://longbridge.com/en/news/273659137.md) | | 汉霖生物在 2/3 期乳腺癌药物研究中为首位患者用药；股价下跌 3% | 恒瑞医药在二期/三期乳腺癌药物研究中为首位患者给药；股价下跌 3% | [Link](https://longbridge.com/en/news/277421361.md) | | 在香港上市的中国制药公司有望通过销售增长和交易来实现转机 | 在香港上市的中国制药公司由于药品销售增长和丰厚的许可交易，正准备实现盈利。信达生物预计在 2025 年将首次实现全年的利润，达到 9.84 亿元人民币，主要得益于 45% 的收入增长。百济神州报告净利润为 2.8693 亿美元，得益于其成功 | [Link](https://longbridge.com/en/news/277340041.md) | | 零散的 Lapsus$猎手正在试音女性声音以增强社会工程能力 | 一个活跃的网络犯罪团伙 Scattered Lapsus$ Hunters (SLSH) 正在招募女性，以增强其社会工程策略，成功拨打电话可获得 500 至 1000 美元的报酬。该团伙旨在通过使用女性声音来欺骗 IT 帮助台工作人员，从而 | [Link](https://longbridge.com/en/news/277042422.md) | | vMOX 与 Advantage Communications Group 完成合并 | 移动管理解决方案公司 vMOX 已与 Advantage Communications Group 合并，以增强全球客户的托管服务。此次合并旨在通过整合 vMOX 的移动管理解决方案来扩展 Advantage 的产品。Advantage 从 | [Link](https://longbridge.com/en/news/277450847.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.